Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Aug 5, 2025
-- Second quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $48.5 million --
-- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 --
Read more at globenewswire.com
